Why would you use it if you don't fully understand that?
In the long human effort to outpace inherited suffering, a team at Columbia University has achieved something quietly remarkable: the precise rewriting of single DNA letters in human embryos, targeting the roots of heart disease and blood disorders. The technique, called base editing, is more surgical than anything that came before it — and yet its very elegance has reignited one of medicine's most enduring moral questions, about who controls the code of life and whether the promise of healing can be separated from the temptation of perfection. The science is not ready for the clinic, its authors insist, but history has shown that readiness and ambition do not always wait for each other.
- A Columbia team's preprint on base editing human embryos arrived without peer review but with immediate global weight, forcing a reckoning the field was not quite prepared to have.
- The edits worked — but imperfectly, with mosaicism leaving some cells changed and others untouched, and the delivery mechanism itself toxic to embryos at higher doses.
- Bioethicists warn that the technique's relative affordability makes it accessible to wealthy individuals who may treat the research as permission rather than as a cautionary map.
- The ghost of He Jiankui — imprisoned for editing embryos that became living children — haunts every discussion, a reminder that scientific condemnation arrives after the irreversible has already occurred.
- Researchers are divided not just on safety but on necessity: IVF with genetic screening already prevents inherited disease, leaving enhancement, not treatment, as the more likely commercial destination.
On June 1st, Dieter Egli's team at Columbia University posted preprint results showing they had used base editing to make precise single-letter DNA changes in human embryos — targeting genes linked to heart disease, sickle cell disease, and thalassemia. Unlike older CRISPR methods that cut both strands of DNA and risk unwanted mutations, base editing makes surgical alterations. In the PCSK9 gene, the team replicated a naturally occurring variant that protects against heart attack. In two hemoglobin genes, they mimicked a mutation that shields certain populations from blood disorders.
But Egli was candid about the work's limits. The edits were inconsistent across cells — a problem called mosaicism — and the delivery machinery caused cells to stop dividing at higher doses. "These base editors can have damaging effects on the embryo," he said. "Why would you use it if you don't fully understand that?" His team has since refined their approach, but the research remains firmly in the laboratory.
The scientific community's reaction was divided. Some praised the work as a careful conceptual advance. Others, like Stanford bioethicist Hank Greely, worried that the technique's relative simplicity — achievable with an IVF lab and genetic testing facility for millions, not billions — could embolden affluent individuals to attempt premature applications with devastating consequences for any children born from them.
The field is still processing the He Jiankui scandal, in which a Chinese scientist implanted CRISPR-edited embryos in 2018, resulting in gene-edited births, global outrage, and a three-year prison sentence. He recently told the New York Times he remained proud of what he had done.
Some researchers, including Fyodor Urnov at UC Berkeley, argue the deeper danger is not therapeutic use but enhancement — that this work will accelerate a movement toward editing embryos for intelligence or athleticism rather than disease. The tension between genuine medical promise and the pull of premature commercialization remains unresolved, and the field must now decide what kind of future it is actually building toward.
On the first of June, a team of researchers led by Dieter Egli at Columbia University posted results to a preprint server that would reshape the conversation around human embryo editing. They had used a technique called base editing to alter the genetic code of human embryos with unprecedented precision—changing single letters of DNA to target diseases like heart disease and blood disorders. The work had not yet been peer reviewed, but it was already drawing intense scrutiny from scientists and ethicists who saw in it both genuine promise and genuine peril.
Base editing represents a significant refinement over earlier genome-editing methods. Where the older CRISPR-Cas9 technique cuts both strands of DNA, introducing the risk of unwanted mutations, base editing makes surgical single-letter changes. Egli's team demonstrated this by targeting three genes: PCSK9, which regulates cholesterol levels and is already the focus of heart disease treatments; and HBG1 and HBG2, which govern fetal hemoglobin production and could potentially help patients with sickle cell disease and thalassemia. In the PCSK9 gene, they changed an A to a G, effectively silencing it—mimicking a naturally occurring variant that protects against heart attack and stroke. The same A-to-G swap in the hemoglobin genes replicated a protective mutation found in some populations.
Yet the work carries significant limitations that Egli himself emphasizes. The edits did not occur uniformly across all cells in the embryos. Some cells received the change while others retained the original sequence—a phenomenon called mosaicism that complicates any future therapeutic use. More troubling, the molecular machinery used to deliver the DNA editor caused cells to stop dividing when administered at higher doses. Egli is clear about the implications: the technology is not ready for clinical use. "These base editors can have damaging effects on the embryo," he said. "Why would you use it if you don't fully understand that?"
The scientific community's response split along predictable lines. Emre Seli, an obstetrician at Yale, called the work a conceptual shift with genuine potential to advance the field. Greg Neely, a genomics researcher in Sydney, praised it as more careful and ethical than previous attempts. But bioethicist Hank Greely at Stanford voiced a concern that animated much of the skepticism: the technology's relative simplicity. An IVF lab and genetic testing facility could be established for millions of dollars—not billions. Affluent individuals might view this work as a green light to attempt embryo editing themselves, Greely warned, with potentially catastrophic results for any children born from such efforts.
Egli counters that his data demonstrate exactly why such premature attempts would be reckless. The risks remain substantial. The mosaicism problem alone makes clinical application premature. His team has since refined their procedures to reduce this effect, but the work remains in the laboratory stage.
The field carries the weight of recent history. In 2018, Chinese scientist He Jiankui used CRISPR-Cas9 to edit human embryos and implanted them into two women, resulting in the birth of gene-edited babies. The revelation sparked global outrage. Scientists condemned the work as reckless and premature. He spent three years in prison for illegal medical practice in China. Yet in January of this year, he told the New York Times he remained "very proud" of what he had done.
That shadow looms over the current work. Some researchers, including Fyodor Urnov at UC Berkeley, argue that embryo editing for disease prevention is solving a problem that already has solutions. Couples can already use IVF combined with genetic screening to avoid passing on genetic conditions to their children. In this view, base editing's real danger lies not in treating disease but in enabling enhancement—the pursuit of superior intelligence, athleticism, or other traits. "This preprint will solely impact the rapidly growing movement of embryo editors for purposes of baby improvement," Urnov said.
The tension is real and unresolved. Base editing is genuinely more precise than what came before. The diseases it could theoretically treat are serious and devastating. But the technology remains crude, the risks poorly understood, and the commercial incentives substantial. The field must now navigate the space between therapeutic possibility and the temptation to rush forward before the science is ready.
Citas Notables
These base editors can have damaging effects on the embryo. Why would you use it if you don't fully understand that?— Dieter Egli, Columbia University
This will go down in history in a positive way—less reckless, more careful and ethical than previous attempts.— Greg Neely, University of Sydney
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this is base editing rather than the older CRISPR technique?
Base editing changes single letters of DNA without cutting both strands. That means fewer unintended mutations, fewer ways the edit can go wrong. It's more like a precise correction than a crude cut-and-paste.
But Egli says it's not ready for use in people. So what's the breakthrough?
The breakthrough is that it works at all in human embryos. Before this, scientists thought the older technique would cause embryos to lose edited chromosomes entirely. This shows a path forward—if they can solve the remaining problems.
What are the remaining problems?
Mosaicism—the edits don't happen in every cell, so you get a patchwork. And at higher doses, the molecular machinery that delivers the editor poisons the cells. Both are solvable in theory, but not yet solved in practice.
Why are people worried about commercialization if the technology isn't ready?
Because it's cheap to set up an IVF lab. A few million dollars, not billions. Once this preprint is out, someone with money and fewer scruples than Egli might decide to try it anyway, before the science is solid.
Is there a legitimate medical use, or is this all about enhancement?
There's a legitimate use—treating sickle cell disease, thalassemia, heart disease. But the skeptics point out that couples can already avoid passing on these conditions using genetic screening. So the real temptation is enhancement: making embryos smarter, stronger, faster.
What does He Jiankui have to do with this?
He's the cautionary tale. He used an earlier, cruder technique to edit embryos and implant them in women. Babies were born. The world was horrified. He went to prison. Now, with a better technique, the temptation to try again is stronger—and the consequences could be worse.